SAVE 30% ON EACH EBOOK AND 60% ON THE COMPLETE BUNDLE!
HSV Statistics: Global Prevalence and What the Data Means
How common are HSV-1, HSV-2 and genital herpes? Review current WHO estimates, their uncertainty and what prevalence data can—and cannot—tell you.
NEWS & RESEARCH
Giles
3/26/20265 min read
What the Latest HSV Numbers Actually Measure
HSV statistics can look contradictory because sources may measure different virus types, body sites, age groups, years and outcomes. A figure for HSV-1 antibodies is not the same as a figure for genital HSV-1, and a clinic diagnosis is not the same as the number of people living with infection.
The latest comprehensive global estimates describe infections in 2020. They were released by the World Health Organization in December 2024 and published in a peer-reviewed journal in 2025. Calling them “2026 data” would confuse the publication date with the year being estimated.
Global HSV Estimates for 2020
WHO reported that around 846 million people aged 15–49—more than one in five people in that age group—were living with a genital HSV-1 or HSV-2 infection in 2020. This combined estimate accounts for people who may have both virus types; it should not be created by simply adding the separate totals.
HSV-2: an estimated 519.5 million people aged 15–49, or 13.3%, were living with HSV-2. WHO rounds this to 520 million and 13%.
Genital HSV-1: an estimated 376.2 million people aged 15–49, or 10.2%, had genital HSV-1.
New genital infections: the model estimated 25.6 million new HSV-2 infections and 16.8 million new genital HSV-1 infections during 2020—about 42 million combined.
Symptomatic genital herpes: about 204.6 million people aged 15–49 were estimated to have experienced at least one HSV-attributable genital-ulcer episode in 2020. WHO rounds this to 205 million.
These are modelled estimates with uncertainty intervals, not a count of positive tests. For example, the HSV-2 estimate ranged from 464.3 million to 611.3 million, while the genital HSV-1 estimate ranged from 235.6 million to 483.5 million. The ranges reflect incomplete surveillance and the assumptions needed to combine studies from different regions.
HSV-1 at Any Body Site
WHO estimates that 3.8 billion people under age 50—64% of that global age group—had HSV-1 infection at any site in 2020. Most HSV-1 is oral and is often acquired during childhood, although HSV-1 can also cause genital infection.
The 3.8-billion figure cannot be described as the number of people with cold sores. Many HSV-1 infections cause no recognised symptoms, and an antibody result usually does not show whether infection is oral or genital.
Likewise, the 846-million genital-herpes estimate and the 3.8-billion HSV-1 estimate answer different questions. They should not be combined into a single prevalence percentage.
What the Statistics Show About Men
WHO reports that HSV-2 infects women almost twice as often as men globally, partly because sexual transmission is more efficient from men to women. That does not create a single worldwide “one in nine men” figure. Prevalence varies substantially by age, location, population sampled and testing method.
A frequently quoted United States report found HSV-1 antibodies in 47.8% and HSV-2 antibodies in 11.9% of people aged 14–49. Those results came from the 2015–2016 National Health and Nutrition Examination Survey. In that survey, HSV-2 prevalence was 8.2% among men and 15.9% among women. These figures remain useful historical estimates but should not be labelled as 2026 prevalence.
Newer US laboratory data have been released for the 2021–2023 NHANES cycle, but a raw data release is not the same as a published, weighted national prevalence analysis. Until an authoritative analysis is available, older percentages should be dated clearly.
England: Diagnoses Are Not Prevalence
UK Health Security Agency surveillance recorded 28,779 first-episode genital-herpes diagnoses in sexual-health services in England during 2025, a 3.1% increase from 27,914 in 2024.
This does not mean only 28,779 people acquired genital HSV in England. Clinic data omit unrecognised infections, people who did not seek care and diagnoses made elsewhere. They also cannot establish national HSV antibody prevalence. Diagnosis counts are useful for tracking service activity and trends, while prevalence studies answer a different question.
What Treatment Statistics Mean
CDC guidance says suppressive antiviral treatment reduces recurrence frequency by about 70–80% among people with frequent genital HSV-2 recurrences. That relative reduction applies to the studied outcome and population; it does not mean everyone will be outbreak-free or that treatment removes HSV.
A major transmission trial followed 1,484 immunocompetent, heterosexual, monogamous couples in which one partner had symptomatic genital HSV-2 and the other was HSV-2 negative. Over eight months, HSV-2 acquisition occurred in 3.6% of susceptible partners in the placebo group and 1.9% in the daily-valaciclovir group—a 48% relative reduction.
The trial supports valaciclovir as one part of risk reduction for similar couples. It does not create a universal annual transmission percentage for every HSV type, sexual practice, gender combination or relationship. Condoms and avoiding sexual contact during symptoms can also reduce risk but cannot make it zero. Read our HSV transmission-risk review for the study context.
What the Data Cannot Tell You
Population statistics cannot predict an individual person’s:
number or severity of future outbreaks;
chance of transmitting HSV during one particular encounter;
best treatment plan or dose;
partner’s response to disclosure;
future relationship, marriage or mental-health outcome.
There are no robust universal statistics showing that 60–80% of HSV disclosures are accepted, that support groups reduce depression by a fixed percentage or that people with HSV have a particular marriage rate. Small community surveys, self-selected samples and anecdotal reports should not be presented as population facts.
A 2024 systematic review found varied reasons, strategies and partner responses across STI-disclosure research, but it did not establish a guaranteed acceptance rate or ideal number of dates before disclosure. For practical guidance, read How to Tell Someone You Have Herpes.
How to Read an HSV Statistic
Before relying on a number, ask:
Which virus? HSV-1, HSV-2 or both?
Which body site? Oral, genital or unknown?
Which outcome? Antibodies, recognised symptoms, clinic diagnoses, viral shedding or transmission?
Which population? Country, age range, sex, symptoms and immune status?
Which year? Data year, publication year and webpage-update year may differ.
Estimate or count? Modelled prevalence has uncertainty; clinic totals miss undiagnosed infections.
Relative or absolute risk? A 50% relative reduction could describe a much smaller change in absolute percentage points.
Those questions prevent a population average from becoming a misleading promise about an individual.
What These Numbers Mean in Practice
HSV is common, often unrecognised and unevenly distributed across populations. The numbers can challenge stigma, but prevalence alone does not make an infection medically trivial or determine how someone should feel about a diagnosis.
Use statistics for context. Use qualified clinical advice for testing, treatment, pregnancy and individual transmission questions. If a diagnosis is affecting confidence or mood, our guides to HSV and self-worth and HSV support resources provide practical next steps without invented outcome percentages.
Sources and Further Reading
Last reviewed: 5 October 2026. Written by Giles. This article has not been medically reviewed and is for general education, not diagnosis, personalised risk calculation or treatment advice.
MODERN HSV PLAYBOOK
THE SERIES
© 2026 Modern HSV Playbook. All rights reserved.
SITE
Content for informational purposes only. Not a substitute for professional medical advice.